(5-((4-(benzo[d]thiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)(piperazin-1-yl)methanone hydrochloride

ID: ALA5286478

Max Phase: Preclinical

Molecular Formula: C21H19ClFN7OS

Molecular Weight: 435.49

Names and Identifiers

Canonical SMILES:  Cl.O=C(c1ccc(Nc2ncc(F)c(-c3ccc4scnc4c3)n2)cn1)N1CCNCC1

Standard InChI:  InChI=1S/C21H18FN7OS.ClH/c22-15-11-25-21(28-19(15)13-1-4-18-17(9-13)26-12-31-18)27-14-2-3-16(24-10-14)20(30)29-7-5-23-6-8-29;/h1-4,9-12,23H,5-8H2,(H,25,27,28);1H

Standard InChI Key:  ZFZGGEQJORZBKU-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    5.3169   -0.7366    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    2.1471    2.6721    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.1471    1.8471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8609    1.4335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8609    0.6085    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1446    0.1972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1446   -0.6277    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4281   -1.0368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4281   -1.8606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7084   -2.2689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0028   -1.8534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7201   -2.2608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4320   -1.8437    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1500   -2.2501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8609   -1.8315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8609   -1.0066    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1360   -0.6001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4320   -1.0187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7201   -3.0858    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0028   -1.0296    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7168   -0.6212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4319    0.6108    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4319    1.4358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7175    1.8483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7175    2.6732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0030    3.0858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7113    2.6732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4957    2.9283    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9807    2.2607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4957    1.5931    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7113    1.8481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0030    1.4356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 13  1  0
 12 19  2  0
 11 20  1  0
 20 21  2  0
 21  8  1  0
  6 22  1  0
 22 23  2  0
 23  3  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 27  1  0
 31 32  2  0
 32 24  1  0
M  END

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 435.49

Molecular Weight (Monoisotopic): 435.1278

AlogP: 3.08

#Rotatable Bonds: 4

Polar Surface Area: 95.93

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.44

CX Basic pKa: 7.82

CX LogP: 2.41

CX LogD: 1.85

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.51

Np Likeness Score: -1.86

References

1. Yuan K, Shen H, Zheng M, Xia F, Li Q, Chen W, Ji M, Yang H, Zhuang X, Cai Z, Min W, Wang X, Xiao Y, Yang P..  (2023)  Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer.,  66  (6): [PMID:36800260] [10.1021/acs.jmedchem.3c00106]

Source

Source(1):

• Scientific Literature